Converted K shares of FIT Biotech have been entered into the Trade Register – FIT Biotech

Reports and Releases

Converted K shares of FIT Biotech have been entered into the Trade Register

FIT Biotech Oy

Company Announcement, September 30, 2015 at 11:00 EET

Converted K shares of FIT Biotech have been entered into the Trade Register

On 8 September 2015, the board of directors of FIT Biotech Oy (the 'Company') decided on the conversion of 3,000 D shares into K shares in accordance with section 5 of the Company's articles of association (1:1). After the conversion, the Company has 27,599,817 K shares, 5,229 A shares and 65,235 D shares. The total number of shares in the Company, 27,670,281, is not affected by the conversion.

The conversions of shares have been entered into the Trade Register on 30 September 2015, and the trading of the converted K shares on First North will begin on or about 1 October 2015.

The Company's K shares are traded under the trading symbol FITBIO on the multilateral First North market maintained by the Helsinki Stock Exchange.

FIT BIOTECH OY

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy
Email: kalevi.reijonen@fitbiotech.com
Phone: +358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU ® (Gene Transport Unit) technology.

Through GTU technology, FIT Biotech develops DNA vaccines in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.

FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com

Back to list